HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine
Authors:
- 15 June 2023
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 152 (1)
Abstract
OBJECTIVES: A single dose of human papillomavirus (HPV) vaccine would simplify logistics and reduce costs of vaccination programs worldwide. We conducted a phase IIa trial to determine the stability of HPV type-specific antibody responses after a single dose of the nonavalent HPV vaccine, Gardasil9. METHODS: Two hundred-and-one healthy 9 to 11-year-old girls and boys were enrolled at 2 centers in the United States to receive a prime dose of the nonavalent vaccine at baseline, a delayed dose at month 24, and an optional third dose at month 30. Blood samples were collected to measure HPV type-specific antibodies at baseline and at 6, 12, 18, 24, and 30 months after the prime dose. The primary outcomes were serum HPV16 and HPV18 antibody responses. RESULTS: In both girls and boys, geometric mean concentrations of HPV16 and HPV18 antibodies increased at 6 months, declined between months 6 to 12, and then remained stable and high (at 20- and 10-times those at baseline for HPV16 and HPV18, respectively) throughout months 12, 18, and 24 (prebooster) visits. Both HPV16 and HPV18 antibody responses demonstrated anamnestic boosting effect at 30-months after the delayed (24-month) booster dose. CONCLUSIONS: A single dose of the nonavalent HPV vaccine induced persistent and stable HPV16 and HPV18 antibody responses up to 24 months. This study contributes important immunogenicity data to inform feasibility of the single dose HPV vaccination paradigm. Further research is needed to assess the long-term antibody stability and individual clinical and public health benefit of the single dose schedule.Keywords
This publication has 19 references indexed in Scilit:
- Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and developmentVaccine, 2018
- Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young womenPapillomavirus Research, 2018
- Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccinationHuman Vaccines & Immunotherapeutics, 2014
- Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three AssaysFrontiers in Oncology, 2014
- Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine TrialCancer Prevention Research, 2013
- Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccinationVaccine, 2012
- Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsMolecular and Cellular Probes, 2012
- Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccineHuman Vaccines, 2008
- Introducing HPV Vaccine in Developing Countries — Key Challenges and IssuesNew England Journal of Medicine, 2007
- Sample Size Calculations in Clinical Research2003